{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:31:42Z","timestamp":1757457102698,"version":"3.37.3"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"29","funder":[{"name":"Xuzhou Special Fund for Promoting Scientific and Technological Innovation","award":["KC23254","KC23217"],"award-info":[{"award-number":["KC23254","KC23217"]}]},{"DOI":"10.13039\/100017962","name":"Medical Research Project of Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["Z2023010"],"award-info":[{"award-number":["Z2023010"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Initializing Fund of Xuzhou Medical University","doi-asserted-by":"publisher","award":["RC20552111","RC20552222"],"award-info":[{"award-number":["RC20552111","RC20552222"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Fusion Innovation Project of Xuzhou Medical University","doi-asserted-by":"publisher","award":["XYRHCX2021011","XYRHCX2022005"],"award-info":[{"award-number":["XYRHCX2021011","XYRHCX2022005"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Education Science Planning Project","award":["C\/2022\/01\/36"],"award-info":[{"award-number":["C\/2022\/01\/36"]}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University Labor Education Special Support Project","doi-asserted-by":"publisher","award":["X1d202209"],"award-info":[{"award-number":["X1d202209"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Higher Education Informatization Research Topic","award":["2023JSETKT136"],"award-info":[{"award-number":["2023JSETKT136"]}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University Research Topic of Higher Education Teaching Reform","doi-asserted-by":"publisher","award":["Xjyzrd202304"],"award-info":[{"award-number":["Xjyzrd202304"]}],"id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Due to the narrow therapeutic window and large pharmacokinetic variation of valproic\nacid (VPA), it is difficult to make an optimal dosage regimen. The present study aims to optimize the initial\ndosage of VPA in patients with bipolar disorder.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A total of 126 patients with bipolar disorder treated by VPA were included to construct the VPA\npopulation pharmacokinetic model retrospectively. Sex differences and combined use of clozapine were found\nto significantly affect VPA clearance in patients with bipolar disorder. The initial dosage of VPA was further\noptimized in male patients without the combined use of clozapine, female patients without the combined use\nof clozapine, male patients with the combined use of clozapine, and female patients with the combined use of\nclozapine, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The CL\/F and V\/F of VPA in patients with bipolar disorder were 11.3 L\/h and 36.4 L, respectively. It\nwas found that sex differences and combined use of clozapine significantly affected VPA clearance in patients\nwith bipolar disorder. At the same weight, the VPA clearance rates were 1.134, 1, 1.276884, and 1.126 in male\npatients without the combined use of clozapine, female patients without the combined use of clozapine, male\npatients with the combined use of clozapine, and female patients with the combined use of clozapine, respectively.\nThis study further optimized the initial dosage of VPA in male patients without the combined use of\nclozapine, female patients without the combined use of clozapine, male patients with the combined use of\nclozapine, and female patients with the combined use of clozapine, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study is the first to investigate the initial dosage optimization of VPA in patients with bipolar\ndisorder based on sex differences and the combined use of clozapine. Male patients had higher clearance,\nand the recommended initial dose decreased with increasing weight, providing a reference for the precision\ndrug use of VPA in clinical patients with bipolar disorder.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113816128323367240704095109","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T10:32:18Z","timestamp":1720607538000},"page":"2290-2302","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Sex Differences and Combined Use of Clozapine on Initial Dosage Optimization of Valproic Acid in Patients with Bipolar Disorder"],"prefix":"10.2174","volume":"30","author":[{"given":"Wei","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Suqian Clinical College of Xuzhou Medical University, Suqian, Jiangsu 223800, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[{"name":"Jiangsu\nKey Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu\n221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Zhe","family":"Shi","sequence":"additional","affiliation":[{"name":"Jiangsu\nKey Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu\n221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Jiangsu\nKey Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu\n221004, China"},{"name":"Department of Pharmacy, Taixing People's Hospital, Taixing, Jiangsu 225400, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiangsu\nKey Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu\n221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Mei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nSuzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nXuzhou Oriental Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Nursing,\nXuzhou Medical University, Xuzhou, Jiangsu 221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu\nKey Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu\n221004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"Carvalho A.F.","year":"2020","unstructured":"Carvalho A.F.; Firth J.; Vieta E.; Bipolar disorder. N Engl J Med  2020,383(1),58-66","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","volume":"396","author":"McIntyre R.S.","year":"2020","unstructured":"McIntyre R.S.; Berk M.; Brietzke E.; Goldstein B.I.; L\u00f3pez-Jaramillo C.; Kessing L.V.; Malhi G.S.; Nierenberg A.A.; Rosenblat J.D.; Majeed A.; Vieta E.; Vinberg M.; Young A.H.; Mansur R.B.; Bipolar disorders. Lancet  2020,396(10265),1841-1856","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","volume":"3","author":"Vigo D.","year":"2016","unstructured":"Vigo D.; Thornicroft G.; Atun R.; Estimating the true global burden of mental illness. Lancet Psychiatry  2016,3(2),171-178","journal-title":"Lancet Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.neubiorev.2020.12.031","volume":"122","author":"Rantala M.J.","year":"2021","unstructured":"Rantala M.J.; Luoto S.; Borr\u00e1z-Le\u00f3n J.I.; Krams I.; Bipolar disorder: An evolutionary psychoneuroimmunological approach. Neurosci Biobehav Rev  2021,122,28-37","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41380-020-0831-4","volume":"26","author":"Haggarty S.J.","year":"2021","unstructured":"Haggarty S.J.; Karmacharya R.; Perlis R.H.; Advances toward precision medicine for bipolar disorder: Mechanisms and molecules. Mol Psychiatry  2021,26(1),168-185","journal-title":"Mol Psychiatry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"18008","DOI":"10.1038\/nrdp.2018.8","volume":"4","author":"Vieta E.","year":"2018","unstructured":"Vieta E.; Berk M.; Schulze T.G.; Carvalho A.F.; Suppes T.; Calabrese J.R.; Gao K.; Miskowiak K.W.; Grande I.; Bipolar disorders. Nat Rev Dis Primers  2018,4(1),18008","journal-title":"Nat Rev Dis Primers"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jad.2019.08.071","volume":"260","author":"Fontana E.","year":"2020","unstructured":"Fontana E.; Mandolini G.M.; Delvecchio G.; Bressi C.; Soares J.C.; Brambilla P.; Intravenous valproate in the treatment of acute manic episode in bipolar disorder: A review. J Affect Disord  2020,260,738-743","journal-title":"J Affect Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40291-018-0335-y","volume":"22","author":"Pisanu C.","year":"2018","unstructured":"Pisanu C.; Heilbronner U.; Squassina A.; The role of pharmacogenomics in bipolar disorder: Moving towards precision medicine. Mol Diagn Ther  2018,22(4),409-420","journal-title":"Mol Diagn Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"CD003196","DOI":"10.1002\/14651858.CD003196.pub2","volume":"2013","author":"Cipriani A.","year":"2013","unstructured":"Cipriani A.; Reid K.; Young A.H.; Macritchie K.; Geddes J.; Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Libr  2013,2013(10),CD003196","journal-title":"Cochrane Libr"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jad.2024.04.071","volume":"356","author":"Arnbjerg C.J.","year":"2024","unstructured":"Arnbjerg C.J.; Musoni-Rwililiza E.; Rurangwa N.U.; Bendtsen M.G.; Murekatete C.; Gishoma D.; Carlsson J.; Kallestrup P.; Effectiveness of structured group psychoeducation for people with bipolar disorder in Rwanda: A randomized open-label superiority trial. J Affect Disord  2024,356,405-413","journal-title":"J Affect Disord"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jad.2024.04.033","volume":"356","author":"Azevedo J.","year":"2024","unstructured":"Azevedo J.; Swales M.; Carreiras D.; Guiomar R.; Macedo A.; Castilho P.; BI-REAL: A 12-session DBT skills group intervention adapted for bipolar disorder \u2013 A feasibility randomised pilot trial. J Affect Disord  2024,356,394-404","journal-title":"J Affect Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jad.2024.05.020","volume":"358","author":"Chen P.H.","year":"2024","unstructured":"Chen P.H.; Hsiao C.Y.; Chiang S.J.; Chung K.H.; Tsai S.Y.; Association of lipids and inflammatory markers with left ventricular wall thickness in patients with bipolar disorder. J Affect Disord  2024,358,12-18","journal-title":"J Affect Disord"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2024.03.095","volume":"355","author":"Chen Z.","year":"2024","unstructured":"Chen Z.; Wang B.; Huang Y.; Wang X.; Li W.; Wang M.; Pathogenesis or a response to lithium? A novel perspective for mitochondrial mass fluctuation of na\u00efve T cells in patients with bipolar disorder. J Affect Disord  2024,355,86-94","journal-title":"J Affect Disord"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/wps.21213","volume":"23","author":"Holm M.","year":"2024","unstructured":"Holm M.; Tanskanen A.; Tiihonen J.; Taipale H.; Medication use and sickness absence from work in bipolar disorder: A nationwide register-based study. World Psychiatry  2024,23(2),296-298","journal-title":"World Psychiatry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.apnu.2024.03.011","volume":"50","author":"Karaca A.","year":"2024","unstructured":"Karaca A.; \u015eener D.K.; Kundak\u00e7i N.; Being a child of a parent with a diagnosis of schizophrenia or bipolar disorder: A qualitative study. Arch Psychiatr Nurs  2024,50,94-99","journal-title":"Arch Psychiatr Nurs"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jad.2024.03.126","volume":"355","author":"Klaus F.","year":"2024","unstructured":"Klaus F.; Ng H.X.; Barbosa I.G.; Beunders A.; Briggs F.; Burdick K.E.; Dols A.; Forlenza O.; Gildengers A.; Millett C.; Mulsant B.H.; Orhan M.; Rajji T.K.; Rej S.; Sajatovic M.; Sarna K.; Schouws S.; Sutherland A.; Teixeira A.L.; Yala J.A.; Eyler L.T.; Cognition in older age bipolar disorder: An analysis of archival data across the globe. J Affect Disord  2024,355,231-238","journal-title":"J Affect Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jad.2024.05.034","volume":"358","author":"Knorr U.","year":"2024","unstructured":"Knorr U.; Simonsen A.H.; Nilsson J.; Brinkmalm A.; Zetterberg H.; Blennow K.; Knudsen M.B.; Forman J.; Hasselbalch S.G.; Kessing L.V.; Cerebrospinal fluid synaptic biomarker changes in bipolar disorder \u2013 A longitudinal case-control study. J Affect Disord  2024,358,250-259","journal-title":"J Affect Disord"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.scog.2024.100309","volume":"37","author":"Lane E.","year":"2024","unstructured":"Lane E.; Joshi D.; Guimond S.; Moore R.; Ahmed A.O.; Ajilore O.; Torous J.; Exploring current smartphone-based cognitive assessments in schizophrenia and bipolar disorder. Schizophr Res Cogn  2024,37,100309","journal-title":"Schizophr Res Cogn"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"152477","DOI":"10.1016\/j.comppsych.2024.152477","volume":"132","author":"Musoni-Rwililiza E.","year":"2024","unstructured":"Musoni-Rwililiza E.; Arnbjerg C.J.; Rurangwa N.U.; Carlsson J.; Kallestrup P.; Vindbjerg E.; Gishoma D.; Adaption and validation of the Rwandese version of the Mood Disorder Questionnaire for the screening of bipolar disorder. Compr Psychiatry  2024,132,152477","journal-title":"Compr Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"110962","DOI":"10.1016\/j.pnpbp.2024.110962","volume":"132","author":"Porta-Caster\u00e0s D.","year":"2024","unstructured":"Porta-Caster\u00e0s D.; Vicent-Gil M.; Serra-Blasco M.; Navarra-Ventura G.; Sol\u00e9 B.; Montejo L.; Torrent C.; Martinez-Aran A.; De la Pe\u00f1a-Arteaga V.; Palao D.; Vieta E.; Cardoner N.; Cano M.; Increased grey matter volumes in the temporal lobe and its relationship with cognitive functioning in euthymic patients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry  2024,132,110962","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jad.2024.05.050","volume":"358","author":"Stacey D.","year":"2024","unstructured":"Stacey D.; Suppiah V.; Benyamin B.; Lee S.H.; Hypp\u00f6nen E.; In-silico functional analyses identify TMPRSS15-mediated intestinal absorption of lithium as a modulator of lithium response in bipolar disorder. J Affect Disord  2024,358,416-421","journal-title":"J Affect Disord"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jad.2024.03.113","volume":"355","author":"Teng Z.","year":"2024","unstructured":"Teng Z.; Xu X.; Chen X.; Qiu Y.; Li S.; Chen J.; Tang H.; Xiang H.; Wang B.; Tan Y.; Wu H.; Increased circulating cell-free mitochondrial DNA in plasma of first-diagnosed drug-na\u00efve bipolar disorder patients: A case-control and 4-week follow-up study. J Affect Disord  2024,355,378-384","journal-title":"J Affect Disord"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2024.03.114","volume":"356","author":"Wang T.","year":"2024","unstructured":"Wang T.; Yang J.; Zhu Y.; Niu N.; Ding B.; Wang P.; Zhao H.; Li N.; Chao Y.; Gao S.; Dong X.; Wang Z.; Evaluation of metabolomics-based urinary biomarker models for recognizing major depression disorder and bipolar disorder. J Affect Disord  2024,356,1-12","journal-title":"J Affect Disord"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jad.2024.04.012","volume":"356","author":"Zhou Z.","year":"2024","unstructured":"Zhou Z.; Xu Z.; Lai W.; Chen X.; Zeng L.; Qian L.; Liu X.; Jiang W.; Zhang Y.; Hou G.; Reduced myelin content in bipolar disorder: A study of inhomogeneous magnetization transfer. J Affect Disord  2024,356,363-370","journal-title":"J Affect Disord"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41398-023-02445-y","volume":"13","author":"Chen Z.","year":"2023","unstructured":"Chen Z.; Huang Y.; Wang B.; Peng H.; Wang X.; Wu H.; Chen W.; Wang M.; T cells: An emerging cast of roles in bipolar disorder. Transl Psychiatry  2023,13(1),153","journal-title":"Transl Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"Perucca E.","year":"2002","unstructured":"Perucca E.; Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs  2002,16(10),695-714","journal-title":"CNS Drugs"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/j.1440-1614.2006.01815.x","volume":"40","author":"Bowden C.L.","year":"2006","unstructured":"Bowden C.L.; Karren N.U.; Anticonvulsants in bipolar disorder. Aust N Z J Psychiatry  2006,40(5),386-393","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"479364","DOI":"10.1155\/2010\/479364","volume":"2010","author":"Chateauvieux S.","year":"2010","unstructured":"Chateauvieux S.; Morceau F.; Dicato M.; Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol  2010,2010,479364","journal-title":"J Biomed Biotechnol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"890221","DOI":"10.3389\/fphar.2022.890221","volume":"13","author":"Zheng P.","year":"2022","unstructured":"Zheng P.; Yu Z.; Mo L.; Zhang Y.; Lyu C.; Yu Y.; Zhang J.; Hao X.; Wei H.; Gao F.; Li Y.; An individualized medication model of sodium valproate for patients with bipolar disorder based on machine learning and deep learning techniques. Front Pharmacol  2022,13,890221","journal-title":"Front Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.4088\/JCP.1108e32","volume":"69","author":"Thase M.E.","year":"2008","unstructured":"Thase M.E.; Maintenance therapy for bipolar disorder. J Clin Psychiatry  2008,69(11),e32","journal-title":"J Clin Psychiatry"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jad.2005.01.002","volume":"86","author":"Revicki D.A.","year":"2005","unstructured":"Revicki D.A.; Hirschfeld R.M.A.; Ahearn E.P.; Weisler R.H.; Palmer C.; Keck P.E.; Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: Results of a naturalistic clinical trial. J Affect Disord  2005,86(2-3),183-193","journal-title":"J Affect Disord"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.eclinm.2022.101678","volume":"54","author":"Chen Y.C.B.","year":"2022","unstructured":"Chen Y.C.B.; Liang C.S.; Wang L.J.; Hung K.C.; Carvalho A.F.; Solmi M.; Vieta E.; Tseng P.T.; Lin P.Y.; Tu Y.K.; Hsu C.W.; Lai E.C.C.; Comparative effectiveness of valproic acid in different serum concentrations for maintenance treatment of bipolar disorder: A retrospective cohort study using target trial emulation framework. EClinicalMedicine  2022,54,101678","journal-title":"EClinicalMedicine"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","volume":"29","author":"Fleming J.","year":"2006","unstructured":"Fleming J.; Chetty M.; Therapeutic monitoring of valproate in psychiatry: How far have we progressed? Clin Neuropharmacol  2006,29(6),350-360","journal-title":"Clin Neuropharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"Methaneethorn J.","year":"2018","unstructured":"Methaneethorn J.; A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol  2018,84(5),816-834","journal-title":"Br J Clin Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/WNL.44.8.1418","volume":"44","author":"Gidal B.","year":"1994","unstructured":"Gidal B.; Spencer N.; Maly M.; Pitterle M.; Williams E.; Collins M.; Jones J.; Valproate-mediated disturbances of hemostasis. Neurology  1994,44(8),1418-1422","journal-title":"Neurology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/pharmaceutics14040811","volume":"14","author":"Teixeira-da-Silva P.","year":"2022","unstructured":"Teixeira-da-Silva P.; P\u00e9rez-Blanco J.S.; Santos-Buelga D.; Otero M.J.; Garc\u00eda M.J.; Population pharmacokinetics of valproic acid in pediatric and adult caucasian patients. Pharmaceutics  2022,14(4),811","journal-title":"Pharmaceutics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00228-021-03246-2","volume":"78","author":"Zang Y.N.","year":"2022","unstructured":"Zang Y.N.; Guo W.; Niu M.X.; Bao S.; Wang Q.; Wang Y.; Dong F.; Li A.N.; Ruan C.J.; Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder. Eur J Clin Pharmacol  2022,78(3),405-418","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00228-020-03080-y","volume":"77","author":"Gu X.","year":"2021","unstructured":"Gu X.; Zhu M.; Sheng C.; Yu S.; Peng Q.; Ma M.; Hu Y.; Li Z.; Jiao Z.; Zhou B.; Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: A protein binding model. Eur J Clin Pharmacol  2021,77(7),999-1009","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/jaoacint\/qsac146","volume":"106","author":"El Orche A.","year":"2023","unstructured":"El Orche A.; Cheikh A.; Johnson J.B.; Elhamdaoui O.; Jawhari S.; El Abbes F.M.; Cherrah Y.; Mbarki M.; Bouatia M.; A novel approach for therapeutic drug monitoring of valproic acid using FT-IR spectroscopy and nonlinear support vector regression. J AOAC Int  2023,106(4),1070-1076","journal-title":"J AOAC Int"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1177\/0267659120972272","volume":"36","author":"Hunt M.F.","year":"2021","unstructured":"Hunt M.F.; Clark K.T.; Grant M.C.; Choi C.W.; Whitman G.; Cho S.M.; Farrokh S.; Therapeutic drug monitoring of valproic acid in extracorporeal membrane oxygenation. Perfusion  2021,36(8),868-872","journal-title":"Perfusion"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/dmd.123.001539","volume":"52","author":"Li R.","year":"2024","unstructured":"Li R.; Chen Z.; Tang S.; Wen D.; Ren R.; Zhang X.; Liu S.; Zhou S.; Wang X.; Zhou L.; Huang M.; Association of valproic acid and its main metabolites\u2019 plasma concentrations with clinical outcomes among epilepsy patients: A 10-year retrospective study based on therapeutic drug monitoring. Drug Metab Dispos  2024,52(3),210-217","journal-title":"Drug Metab Dispos"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e4603","DOI":"10.1002\/jms.4603","volume":"56","author":"Li Y.","year":"2021","unstructured":"Li Y.; Jiang Y.; Cao H.; Lin H.; Ren W.; Huang J.; Zhang J.; Therapeutic drug monitoring of valproic acid using a dried plasma spot sampling device. J Mass Spectrom  2021,56(4),e4603","journal-title":"J Mass Spectrom"},{"key":"ref=43","first-page":"1773","volume":"31","author":"Shaikh A.S.","year":"2018","unstructured":"Shaikh A.S.; Liu H.; Li Y.; Cao L.; Guo R.; Therapeutic drug monitoring of valproic acid. Pak J Pharm Sci  2018,31(4(Special)),1773-1776","journal-title":"Pak J Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.4102\/ajlm.v11i1.1628","volume":"11","author":"Singu B.S.","year":"2022","unstructured":"Singu B.S.; Morrison H.; Irengeya L.; Verbeeck R.K.; Therapeutic drug monitoring of phenytoin and valproic acid in critically ill patients at Windhoek Central Hospital, Namibia. Afr J Lab Med  2022,11(1),1628","journal-title":"Afr J Lab Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/DDDT.S432439","volume":"18","author":"Ahmed K.","year":"2024","unstructured":"Ahmed K.; Ibrahim A.; Gonzalez D.; Nur A.; Population pharmacokinetics and model-based dose optimization of vancomycin in sudanese adult patients with renal impairment. Drug Des Devel Ther  2024,18,81-95","journal-title":"Drug Des Devel Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e01400-23","DOI":"10.1128\/aac.01400-23","volume":"68","author":"Bulitta J.B.","year":"2024","unstructured":"Bulitta J.B.; Fang E.; Stryjewski M.E.; Wang W.; Atiee G.J.; Stark J.G.; Hafkin B.; Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens. Antimicrob Agents Chemother  2024,68(4),e01400-23","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e002003","DOI":"10.1136\/bmjpo-2023-002003","volume":"7","author":"Feng H.","year":"2023","unstructured":"Feng H.; Wang X.; Zheng W.; Liu S.; Jiang H.; Lin Y.; Qiu H.; Chan T.F.; Huang M.; Li Y.; Mo X.; Li J.; Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: A retrospective study. BMJ Paediatr Open  2023,7(1),e002003","journal-title":"BMJ Paediatr Open"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2174\/0113816128307797240416053723","volume":"30","author":"Han H.H.","year":"2024","unstructured":"Han H.H.; Rui M.; Yang Y.; Cui J.F.; Huang X.T.; Zhang S.J.; He S.M.; Wang D.D.; Chen X.; The impact of spironolactone co-administration on cyclosporin initial dosage optimization for pediatric refractory nephrotic syndrome. Curr Pharm Des  2024,30(18),1419-1432","journal-title":"Curr Pharm Des"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/jcpt.13407","volume":"46","author":"Jing Y.","year":"2021","unstructured":"Jing Y.; Kong Y.; Hou X.; Liu H.; Fu Q.; Jiao Z.; Peng H.; Wei X.; Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. J Clin Pharm Ther  2021,46(4),1117-1128","journal-title":"J Clin Pharm Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1111\/bcp.15855","volume":"89","author":"Li X.","year":"2023","unstructured":"Li X.; Cheng Y.; Chen B.; Chen Y.; Huang Y.; Zhang B.; Que W.; Liu M.; Zhang H.; Qiu H.; Population pharmacokinetics of polymyxin B in patients with liver dysfunction. Br J Clin Pharmacol  2023,89(12),3561-3572","journal-title":"Br J Clin Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s13318-022-00781-w","volume":"47","author":"Lim C.P.","year":"2022","unstructured":"Lim C.P.; Tseng S.H.; Neoh C.C.C.; Chen Q.; Poon W.B.; External validation of a vancomycin population pharmacokinetic model and developing a new dosage regimen in neonates. Eur J Drug Metab Pharmacokinet  2022,47(5),687-697","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/jac\/dkab302","volume":"76","author":"Shimamoto Y.","year":"2021","unstructured":"Shimamoto Y.; Verstegen R.H.J.; Mizuno T.; Schechter T.; Allen U.; Ito S.; Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: Development of new dosing recommendations. J Antimicrob Chemother  2021,76(11),2932-2940","journal-title":"J Antimicrob Chemother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/phar.2771","volume":"43","author":"Wang C.","year":"2023","unstructured":"Wang C.; Chen J.; Yang B.; Li S.; Zhang Y.; Chen L.; Wang T.; Dong Y.; Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy  2023,43(3),180-188","journal-title":"Pharmacotherapy"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"994665","DOI":"10.3389\/fphar.2022.994665","volume":"13","author":"Zhu X.","year":"2022","unstructured":"Zhu X.; Zhang M.; Wen Y.; Shang D.; Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example. Front Pharmacol  2022,13,994665","journal-title":"Front Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/jvp.12156","volume":"38","author":"Egelund E.F.","year":"2015","unstructured":"Egelund E.F.; Isaza R.; Brock A.P.; Alsultan A.; An G.; Peloquin C.A.; Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. J Vet Pharmacol Ther  2015,38(2),137-143","journal-title":"J Vet Pharmacol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1213\/ANE.0000000000004766","volume":"131","author":"Eley V.A.","year":"2020","unstructured":"Eley V.A.; Christensen R.; Ryan R.; Jackson D.; Parker S.L.; Smith M.; van Zundert A.A.; Wallis S.C.; Lipman J.; Roberts J.A.; Prophylactic cefazolin dosing in women with body mass index >35 kg\u00b7m undergoing cesarean delivery: A pharmacokinetic study of plasma and interstitial fluid. Anesth Analg  2020,131(1),199-207","journal-title":"Anesth Analg"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijid.2021.01.033","volume":"104","author":"Fredj N.B.","year":"2021","unstructured":"Fredj N.B.; Romdhane H.B.; Woillard J.B.; Chickaid M.; Fadhel N.B.; Chadly Z.; Chaabane A.; Boughattas N.; Aouam K.; Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia. Int J Infect Dis  2021,104,562-567","journal-title":"Int J Infect Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1021\/acs.molpharmaceut.6b00677","volume":"14","author":"Kim T.H.","year":"2017","unstructured":"Kim T.H.; Shin S.; Bulitta J.B.; Youn Y.S.; Yoo S.D.; Shin B.S.; Development of a physiologically relevant population pharmacokinetic in vitro \u2013 in vivo correlation approach for designing extended-release oral dosage formulation. Mol Pharm  2017,14(1),53-65","journal-title":"Mol Pharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fphar.2018.00603","volume":"9","author":"Li Z.","year":"2018","unstructured":"Li Z.; Liu Y.; Jiao Z.; Qiu G.; Huang J.; Xiao Y.; Wu S.; Wang C.; Hu W.; Sun H.; Population pharmacokinetics of vancomycin in chinese ICU neonates: Initial dosage recommendations. Front Pharmacol  2018,9,603","journal-title":"Front Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.clinthera.2019.04.027","volume":"41","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Qiu T.; Liu Y.; Wang J.; Hu K.; Bao F.; Zhang C.; Model-based voriconazole dose pptimization in Chinese adult patients with hematologic malignancies. Clin Ther  2019,41(6),1151-1163","journal-title":"Clin Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1093\/jac\/dkz265","volume":"74","author":"Mehta K.","year":"2019","unstructured":"Mehta K.; Ravimohan S.; Pasipanodya J.G.; Srivastava S.; Modongo C.; Zetola N.M.; Weissman D.; Ivaturi V.; Gumbo T.; Bisson G.P.; Vinnard C.; Optimizing ethambutol dosing among HIV\/tuberculosis co-infected patients: A population pharmacokinetic modelling and simulation study. J Antimicrob Chemother  2019,74(10),2994-3002","journal-title":"J Antimicrob Chemother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jac\/dky466","volume":"74","author":"Milliken E.","year":"2019","unstructured":"Milliken E.; de Zwart A.E.S.; Alffenaar J.W.C.; Marriott D.J.E.; Riezebos-Brilman A.; Schteinman A.; Evans A.M.; Glanville A.R.; Verschuuren E.A.M.; Reuter S.E.; Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. J Antimicrob Chemother  2019,74(3),691-698","journal-title":"J Antimicrob Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/jac\/dku429","volume":"70","author":"Ramon-Lopez A.","year":"2015","unstructured":"Ramon-Lopez A.; Allen J.M.; Thomson A.H.; Dheansa B.S.; James S.E.; Hanlon G.W.; Stewart B.; Davies J.G.; Dosing regimen of meropenem for adults with severe burns: A population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother  2015,70(3),882-890","journal-title":"J Antimicrob Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"106841","DOI":"10.1016\/j.ijantimicag.2023.106841","volume":"62","author":"Rao Q.","year":"2023","unstructured":"Rao Q.; Yang Y.; Wang S.; Zhu H.; Jin L.; Zhang J.; Liu M.; Optimal dosing regimen of biapenem based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies. Int J Antimicrob Agents  2023,62(1),106841","journal-title":"Int J Antimicrob Agents"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/FTD.0000000000001008","volume":"44","author":"Liao M.","year":"2022","unstructured":"Liao M.; Wang M.; Zhu X.; Zhao L.; Zhao M.; Tacrolimus population pharmacokinetic model in adult Chinese patients with nephrotic syndrome and dosing regimen identification using monte carlo simulations. Ther Drug Monit  2022,44(5),615-624","journal-title":"Ther Drug Monit"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jcph.810","volume":"57","author":"Xu H.","year":"2017","unstructured":"Xu H.; Zhou W.; Zhou D.; Li J.; Al-Huniti N.; Evaluation of aztreonam dosing regimens in patients with normal and impaired renal function: A population pharmacokinetic modeling and monte carlo simulation analysis. J Clin Pharmacol  2017,57(3),336-344","journal-title":"J Clin Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"Anderson B.J.","year":"2008","unstructured":"Anderson B.J.; Holford N.H.G.; Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol  2008,48(1),303-332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=68","first-page":"9","volume":"51","author":"Hiemke C.","year":"2017","unstructured":"Hiemke C.; Bergemann N.; Clement HW.; Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry  2017,51(1-2),9-62","journal-title":"Pharmacopsychiatry"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"Yatham L.N.","year":"2018","unstructured":"Yatham L.N.; Kennedy S.H.; Parikh S.V.; Schaffer A.; Bond D.J.; Frey B.N.; Sharma V.; Goldstein B.I.; Rej S.; Beaulieu S.; Alda M.; MacQueen G.; Milev R.V.; Ravindran A.; O\u2019Donovan C.; McIntosh D.; Lam R.W.; Vazquez G.; Kapczinski F.; McIntyre R.S.; Kozicky J.; Kanba S.; Lafer B.; Suppes T.; Calabrese J.R.; Vieta E.; Malhi G.; Post R.M.; Berk M.; Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord  2018,20(2),97-170","journal-title":"Bipolar Disord"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/09540260902962206","volume":"21","author":"Atmaca M.","year":"2009","unstructured":"Atmaca M.; Valproate and neuroprotective effects for bipolar disorder. Int Rev Psychiatry  2009,21(4),410-413","journal-title":"Int Rev Psychiatry"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/17512433.2022.2075849","volume":"15","author":"Zang Y.N.","year":"2022","unstructured":"Zang Y.N.; Guo W.; Dong F.; Li A.N.; de Leon J.; Ruan C.J.; Published population pharmacokinetic models of valproic acid in adult patients: A systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. Expert Rev Clin Pharmacol  2022,15(5),621-635","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00213-005-0272-4","volume":"184","author":"Bazinet R.P.","year":"2006","unstructured":"Bazinet R.P.; Weis M.T.; Rapoport S.I.; Rosenberger T.A.; Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl\u2013CoA by brain microsomal long-chain fatty acyl\u2013CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl)  2006,184(1),122-129","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/jcpt.13280","volume":"46","author":"Methaneethorn J.","year":"2021","unstructured":"Methaneethorn J.; Leelakanok N.; Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients. J Clin Pharm Ther  2021,46(1),198-207","journal-title":"J Clin Pharm Ther"},{"key":"ref=74","first-page":"1576","volume":"25","author":"Jiang D.C.","year":"2004","unstructured":"Jiang D.C.; Wang L.; Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta Pharmacol Sin  2004,25(12),1576-1583","journal-title":"Acta Pharmacol Sin"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","volume":"29","author":"Correa T.","year":"2008","unstructured":"Correa T.; Rodr\u00edguez I.; Romano S.; Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos  2008,29(9),511-520","journal-title":"Biopharm Drug Dispos"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","volume":"27","author":"Park H.M.","year":"2002","unstructured":"Park H.M.; Kang S.S.; Lee Y.B.; Shin D.J.; Kim O.N.; Lee S.B.; Yim D.S.; Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther  2002,27(6),419-425","journal-title":"J Clin Pharm Ther"},{"key":"ref=77","first-page":"1215","volume":"26","author":"Jiao Z.","year":"2021","unstructured":"Jiao Z.; Li X.G.; Sheng D.W.; [Model informed precision dosing: China expert consensus report]. Chin J. Clin Pharmacol Ther  2021,26(11),1215-1228","journal-title":"Clin Pharmacol Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00213-023-06397-5","volume":"240","author":"Tabrisi R.","year":"2023","unstructured":"Tabrisi R.; Harun-Rashid MD.; Montero J.; Clozapine but not lithium reverses aberrant tyrosine uptake in patients with bipolar disorder. Psychopharmacology  2023,240(8),1667-1676","journal-title":"Psychopharmacology"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0000000000001693","volume":"43","author":"Loo LWJ.","year":"2023","unstructured":"Loo LWJ.; Chew QH.; Lin SK.; Clozapine use for bipolar disorder: An asian psychotropic prescription patterns consortium study. J Clin Psychopharmacol  2023,43(3),278-282","journal-title":"J Clin Psychopharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fpsyt.2019.00520","volume":"10","author":"Wilkowska A.","year":"2019","unstructured":"Wilkowska A.; Wiglusz M.S.; Cuba\u0142a W.J.; Clozapine in treatment-resistant bipolar disorder with suicidality. Three case reports. Front Psychiatry  2019,10,520","journal-title":"Front Psychiatry"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.02.026","volume":"125","author":"Delgado A.","year":"2020","unstructured":"Delgado A.; Velosa J.; Zhang J.; Dursun S.M.; Kapczinski F.; de Azevedo Cardoso T.; Clozapine in bipolar disorder: A systematic review and meta-analysis. J Psychiatr Res  2020,125,21-27","journal-title":"J Psychiatr Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/02698811211029738","volume":"35","author":"Forte A.","year":"2021","unstructured":"Forte A.; Pompili M.; Imbastaro B.; De Luca G.P.; Mastrangelo M.; Montalbani B.; Baldessarini R.J.; Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol  2021,35(9),1074-1080","journal-title":"J Psychopharmacol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s43440-020-00157-4","volume":"73","author":"Danek P.J.","year":"2021","unstructured":"Danek P.J.; Basi\u0144ska-Ziobro\u0144 A.; W\u00f3jcikowski J.; Daniel W.A.; Levomepromazine and clozapine induce the main human cytochrome P450 drug metabolizing enzyme CYP3A4. Pharmacol Rep  2021,73(1),303-308","journal-title":"Pharmacol Rep"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128323367240704095109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231784\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128323367240704095109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:30:54Z","timestamp":1731497454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231784\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":83,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128323367240704095109","relation":{},"ISSN":["1381-6128"],"issn-type":[{"type":"print","value":"1381-6128"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}